Cannabis trialled as melanoma treatment by University of Canberra
Researchers at the University of Canberra will collaborate with a pharmaceutical company to test the efficacy of medicinal cannabis in treating melanoma.
The university announced a $1 million deal with Israel-based Cann Pharmaceutical to provide specific medical-grade strains of cannabis, which will be administered to patients along with the current standard of care for melanoma patients.
Molecular and cellular biology professor Sudha Rao said the research could benefit the almost-55,000 Australians that live with the skin cancer.
"Australians have the highest rate of melanoma in the world, with estimates of more than 13,000 new cases to be diagnosed in 2016 alone," she said.
"When you consider that melanoma is the third most common cancer in Australia and New Zealand, and almost 1,800 people will die as a result of this cancer this year, we need to work harder at finding effective treatments."
Professor Rao previously worked on preventing the recurrence...
This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.
Follow us on Instagram
Connect with us on Linkedin